AI-based prediction of five major diseases using integrated health data

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study develops and validates an AI-based predictive model to estimate the risk of incident cardiovascular disease, type 2 diabetes, breast cancer, low back pain, and osteoarthritis in adults aged 30 to 65. It uses a hybrid design that blends retrospective electronic medical records and health data with prospectively collected biospecimen, omics, questionnaire, and digital health information. Data are drawn from about 1,000 participants, including roughly 700 disease-group individuals and healthy controls, with incident status determined by EMR review up to 10 years after an index date. Prospective procedures are brief, aimed at enriching the dataset without long-term follow-up obligations. The study focuses on integrating multimodal data to enhance early risk stratification for these conditions.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Adults aged 30 to 65 years.
2. Disease group: Participants with a confirmed diagnosis of at least one of the following conditions: type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain.
3. Healthy control group: Participants with no prior diagnosis of type 2 diabetes mellitus, breast cancer, cardiovascular disease, osteoarthritis, or low back pain.
4. No history or current diagnosis of major medical conditions that may affect study outcomes, including but not limited to chronic kidney disease or liver cirrhosis.
5. Ability to understand the study procedures and provision of written informed consent prior to participation.

Exclusion Criteria:

1. Participants with incomplete or insufficient clinical or health screening data.
2. Participants considered inappropriate for study participation by the investigator.

Where it's running

• Seoul Asan Medical Center
  Seoul, Seoul Special City, South Korea Recruiting

Study contacts

• Study coordinator: Jaeyong Jeon
• Email: jyjeon71@gmail.com
• Phone: +82-2-3010-3791

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Early risk screening for diabetes and heart disease in Ascoli Piceno

  This project tests a new screening program for 50-year-olds in Ascoli Piceno to see if they are at risk for type 2 diabetes and cardiovascular disease.

  Recruiting at 2 sites Marche Region Regional Health Agency · Ascoli Piceno, Ascoli Piceno and 1 other locations · NCT07344701

• Integrated healthy lifestyle and pain care for people with musculoskeletal conditions in rural areas

  Aiming to see if an in-person or a virtual, lifestyle-focused pain care program helps rural adults with musculoskeletal pain and lifestyle risks feel less impact from their pain.

  Recruiting at 2 sites University of Sydney · Coffs Harbour, New South Wales and 2 other locations · NCT07173335

• Vicadrostat with empagliflozin for people with type 2 diabetes, high blood pressure, and heart disease

  This trial will test whether adding vicadrostat to empagliflozin lowers cardiovascular risk in adults who have type 2 diabetes, high blood pressure, and existing cardiovascular disease but no history of heart failure.

  Recruiting at 1096 sites Phase 3 Boehringer Ingelheim · Anniston, Alabama and 1141 other locations · NCT07064473

• Kefir for vascular and immune health in people with or at risk for type 2 diabetes

  This 12-week test will see if drinking 350 mL of traditional kefir each day helps improve blood vessel and immune health in adults aged 24–70 who have or are at higher risk for type 2 diabetes.

  Recruiting University of Alberta · Edmonton, Alberta · NCT06695221

• Evaluating human placental membrane products for treating nonhealing diabetic foot and venous leg ulcers

  This study is testing whether using human placental products along with regular care can help people with stubborn diabetic foot and leg ulcers heal better.

  Recruiting C5 Biomedical · Metairie, Louisiana · NCT06674980

• Evaluating Enavogliflozin for Heart and Kidney Health in Type 2 Diabetes

  This study is testing if a new diabetes medication called enavogliflozin can improve heart and kidney health in adults with type 2 diabetes compared to other similar medications.

  Recruiting Phase 4 Yonsei University · Seoul · NCT06642623

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.